

Ekaterina Safroneeva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3116363/publications.pdf>

Version: 2024-02-01

73
papers

3,709
citations

172457

29
h-index

133252

59
g-index

73
all docs

73
docs citations

73
times ranked

3363
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 766-775.e4.	4.4	21
2	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
3	Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1729-1738.e1.	4.4	8
4	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multicenter study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2520-2533.	5.7	15
5	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	4.4	57
6	Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis. <i>United European Gastroenterology Journal</i> , 2022, 10, 308-318.	3.8	17
7	Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 87-96.	1.9	1
8	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 33-47.	2.9	5
9	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Gastroenterology</i> , 2022, 163, 59-76.	1.3	33
10	Increasing Incidence of Microscopic Colitis in a Population-Based Cohort Study in Switzerland. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2205-2206.	4.4	6
11	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2514-2523.e2.	4.4	19
12	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 473-483.e17.	4.4	54
13	Food-induced immediate response of the esophagus? A newly identified syndrome in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 339-347.	5.7	22
14	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	1
15	Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 912-919.e2.	1.0	12
16	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 773-780.	3.8	4
17	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 748-755.	1.3	11
18	Emerging Therapies for Eosinophilic Gastrointestinal Diseases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3276-3281.	3.8	15

#	ARTICLE	IF	CITATIONS
19	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 778-784.	1.3	0
20	Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 1169-1193.	2.1	8
21	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 111-122.e10.	1.3	300
22	Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 211-220.	2.1	7
23	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2654-2663.	2.3	4
24	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2456-2462.	4.4	2
25	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 1196-1207.	3.8	24
26	Editorial: fluticasone propionate orally disintegrating tablets "interesting concept but is it going anywhere? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 990-991.	3.7	0
27	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 750-759.	3.7	29
28	Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 2098-2102.	0.4	16
29	Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1334-1342.	1.3	38
30	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	4.4	16
31	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1292-1301.	1.3	37
32	Symptom-based patient-reported outcomes in adults with eosinophilic esophagitis: value for treatment monitoring and randomized controlled trial design. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 169-174.	2.3	5
33	Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 419-428.e6.	4.4	66
34	RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, 592-603.e10.	1.3	182
35	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 811-818.	1.3	88
36	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 612-620.	1.6	30

#	ARTICLE	IF	CITATIONS
37	Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms. <i>American Journal of Gastroenterology</i> , 2018, 113, 348-357.	0.4	32
38	Pharmacologic Treatment of Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 77-88.	1.4	12
39	Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 35-45.	1.4	18
40	Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1082-1090.	3.7	24
41	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 84-93.	3.8	20
42	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	4.4	33
43	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1399-1409.	1.3	40
44	Sa1151 - Baseline Characteristics and Correlation Between Dysphagia and Disease Activity in Patients with Eosinophilic Esophagitis in a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial. <i>Gastroenterology</i> , 2018, 154, S-259.	1.3	6
45	Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 245-247.	1.8	20
46	Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1174-1181.	1.9	72
47	Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept. <i>American Journal of Gastroenterology</i> , 2017, 112, 1527-1535.	0.4	105
48	Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 91-97.	1.6	50
49	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 200-206.	1.8	89
50	Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS). <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 163-170.	1.9	10
51	Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies. <i>Digestive Diseases</i> , 2016, 34, 462-468.	1.9	8
52	167 Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. <i>Gastroenterology</i> , 2016, 150, S43.	1.3	1
53	Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis. <i>Endoscopy</i> , 2016, 48, 1069-1075.	1.8	24
54	Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1200-1205.	1.5	28

#	ARTICLE	IF	CITATIONS
55	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	1.3	251
56	Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia. Current Treatment Options in <i>Gastroenterology</i> , 2016, 14, 51-60.	0.8	3
57	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. <i>Endoscopy</i> , 2016, 48, 256-262.	1.8	45
58	Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1794-1800.	1.9	175
59	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	11
60	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.4	44
61	Pharmacologic Treatment of Eosinophilic Esophagitis. Current Treatment Options in <i>Allergy</i> , 2015, 2, 100-109.	2.2	0
62	Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1207-1218.	1.5	8
63	Activity Assessment of Eosinophilic Esophagitis. <i>Digestive Diseases</i> , 2014, 32, 98-101.	1.9	13
64	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	1.3	221
65	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 191-199.	1.3	37
66	Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent Manner. <i>Gastroenterology</i> , 2013, 145, 1230-1236.e2.	1.3	580
67	Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. <i>American Journal of Gastroenterology</i> , 2013, 108, 1744-1753.	0.4	175
68	Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 332-341.	1.9	240
69	A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 840-846.	1.9	10
70	Influence of the Tissue Microenvironment on Toll-Like Receptor Expression by CD11c ⁺ Antigen-Presenting Cells Isolated from Mucosal Tissues. <i>Vaccine Journal</i> , 2009, 16, 1615-1623.	3.1	9
71	Dendritic Cells Derived from Murine Colonic Mucosa Have Unique Functional and Phenotypic Characteristics. <i>Journal of Immunology</i> , 2007, 178, 7984-7993.	0.8	33
72	The role of ICPO-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. <i>Molecular Therapy</i> , 2005, 12, 1101-1110.	8.2	53

#	ARTICLE	IF	CITATIONS
73	A Cysteine-Free Firefly Luciferase Retains Luminescence Activity. Biochemical and Biophysical Research Communications, 2000, 267, 394-397.	2.1	16